Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People who have been diagnosed with one of the following lung conditions: Idiopathic Pulmonary Fibrosis (IPF), Nonspecific Interstitial Pneumonia (NSIP), Pneumoconioses (lung disease caused by inhaling dust), interstitial lung disease (ILD) linked to autoimmune conditions, Pleuroparenchymal Fibroelastosis (PPFE), Chronic Hypersensitivity Pneumonitis (CHP) not primarily caused by the home environment, Stage 4 fibrosing sarcoidosis, or unclassifiable ILD
- People whose lung scarring (fibrosis) has been getting worse over the past 12 months (case group), or people whose lung scarring has been stable over the past 12 months (control group)
- People whose ILD treatment has not been reduced in the 12 months before joining the trial — those not currently on any treatment may also be eligible
- People who have been informed about the study and do not object to taking part
- People who are registered with, or covered by, a French social security or universal health coverage scheme
- People living in the Île-de-France region
Who may not be able to join:
- People who have already had a consultation at an Environmental and Occupational Medicine Centre (CMEI) in the past 12 months
- People who have moved into their current home less than 1 year ago
- People who spend fewer than 6 months per year living in the home that would be investigated
- People who are currently under psychiatric care for a severe condition
- People who do not speak French and are not accompanied by someone who shares their home and can translate for them
- People who do not wish to consent to taking part in the research
- People who do not live in the Île-de-France region
- People with Hypersensitivity Pneumonitis that is not the chronic form, or where the home environment is the primary cause
- People with sarcoidosis, unless it is specifically Stage 4 fibrosing sarcoidosis
- Adults who are under legal protection and are unable to give their own consent
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jean-Marc NACCACHE, 1, Groupe Hospitalier Paris Saint Josèphe
Phone: +33144978771
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
ILD development linked to exposure to indoor risk factors
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.